Document:

exv10w12

 

	 	 	 	 	 

Exhibit 10.12

SECOND AMENDMENT TO LEASE

          THIS SECOND AMENDMENT TO LEASE (the “Amendment”) is made and entered into as of the date
below written by and between CALIFORNIA PACIFIC COMMERCIAL CORPORATION (“Lessor”) and ALEXZA
MOLECULAR DELIVERY CORPORATION (“Lessee”).

RECITALS

     A. Lessor and Lessee are parties to that certain lease dated March 20, 2002 for certain
premises located at 1001 East Meadow Circle, Palo Alto, California, as amended by that certain
First Amendment to Lease dated May 8, 2003 (collectively, the “Lease”).

     B. Lessor and Lessee desire to amend the terms of the Lease on the terms and conditions set
forth below.

AGREEMENT

          Lessor and Lessee hereby agree as follows:

          1. Term. The term of the Lease is hereby extended until December 31, 2006.

          2.
Base Rent. Through April 30, 2005, base rent shall be Fifty Two Thousand Seventy
Eight Dollars ($52,078) per month. Commencing May 1, 2005 and continuing through May 31, 2006,
base rent shall be One Hundred Twenty Four Thousand Two Hundred Fourteen Dollars ($124,214) per
month. Commencing June 1, 2006, base rent shall be One Hundred Twenty Seven Thousand and Twenty Nine Dollars ($127,029) per month.

          3.
Additional Premises. Commencing May 1, 2005, the Premises shall include all of the
property commonly known as 1020 East Meadow Circle, which includes a single story building
containing approximately 36,993 rentable square feet (the “1020 Premises”). Lessee shall accept the
1020 Premises in its “as is” condition upon delivery thereof by the Lessor; provided, however, that
as a condition to Lessee’s obligation to accept possession of the 1020 Premises, Lessor shall
deliver to Lessee a copy of any required environmental closure authorization issued by the local
fire department or other governmental authority in connection with the cessation of the existing
tenant’s use of the 1020 Premises. Lessor’s failure to deliver such certificate shall not
constitute a breach of this Lease by Lessor, but shall be grounds for Lessee refusing to accept the
1020 Premises. Lessee shall not be responsible for any pre-existing environmental conditions
present at the 1020 Premises at the time Lessor delivers possession of the 1020 Premises. If Lessor
is unable to deliver possession of the 1020 Premises as of the scheduled date for any reason, (i)
rental with respect to the 1020 Premises shall be delayed until Lessor delivers possession of the
1020 Premises to Lessee (with base rent calculated daily at a rate of $1.95 per square foot per
month); and (ii) Lessor shall not be liable for any damage

 

 

caused for failing to deliver
possession, and this Amendment shall not be void or voidable, provided, however, that Lessor shall
provide Lessee with a rental credit (the “Rental Credit”) against base rental owing under this
Lease in an amount equal to Eight Hundred Thirty Three Dollar ($833) for each day that Lessor is
late in delivering the 1020 Premises to Lessee; provided, however, that Lessee shall have the right
to terminate this Amendment on or before August 10, 2005 in the event that Lessor does not deliver
possession of the 1020 Premises to Lessee on or before August 1, 2005. If Lessee terminates this
Amendment pursuant to the preceding sentence, Lessee shall still receive the Rental Credit through
August 1, 2005 and Lessee shall immediately vacate the Temporary Premises. The parties acknowledge
that the Rental Credit is a reasonable estimate of the damages that Lessee will incur as a result
of delay in delivery of the premises as a result of potential disruption in development activities
that require availability of the 1020 Premises.

          4.
Temporary Premises. From February 14, 2005 until Lessor delivers possession of the
1020 Premises to Lessee, the Premises shall include the property commonly known as 1085 East
Meadow Circle (the “Temporary Premises”). Lessee shall accept the Temporary Premises in its “as
is” condition upon delivery thereof by the Lessor; provided, however, that the Temporary Premises
shall contain 25 cubicle partition systems which Lessee may use during its occupancy of the
Temporary Premises. From February 14, 2005 through April 30, 2005, Lessee shall pay Lessor Seven
Thousand Five Hundred Dollars ($7,500) per month as rental for the
Temporary Premises. In the
event that Lessee occupies the Temporary Premises after April 30, 2005 because Lessor has not
delivered the 1020 Premises, Lessee shall not be required to pay any base rent for the Temporary
Premises. The $7,500 rental amount is a gross rental and Lessee shall not be required to pay any
Common Area Operating Expenses with respect to the Temporary Premises other than utilities,
janitorial and garbage charges incurred in connection with its use thereof.

          5.
Additional Security Deposit. Concurrently with the execution and delivery of this
Amendment, Lessee is increasing the security deposit to be held by Lessor in accordance with the
Lease by Seventy Two Thousand One Hundred Thirty Six Dollars ($72,136). Lessee may pay such
additional security deposit in cash or by delivery of a stand-by letter of credit meeting all of
the terms of Section 60 of the Lease. Tenant hereby waives Civil Code Section 1950.7.

          6.
Option to Renew. Provided Lessee is not in default under the terms of the Lease
either at the time of exercise of the option or at commencement of the applicable option period,
Lessee shall have one (1) option to renew the Lease for six (6) months commencing January 1, 2007.
Said option shall be on the same terms, covenants and
conditions contained herein except that the base rent shall be One Hundred Thirty Three
Thousand Five Hundred Forty Three Dollars ($133,543) per month. The option may be exercised only by
written notice to Lessor delivered no later than March 31, 2006. The options set forth in Section 4
of the First Amendment to Lease are hereby terminated.

 

 

          7. Use. The Premises shall be used as research and development, manufacturing,
administrative offices and all other related permitted uses.

          8.
HVAC for 1020 Premises. Notwithstanding Section 2.2 of the Lease, the warranty
period with respect to the HVAC system serving the 1020 Premises shall extend through the term of
the Lease. Lessee shall reimburse Lessor, as a Common Area Operating Expense, for the cost of the
maintenance agreements for and routine repairs and replacements to the HVAC system serving the 1020
Premises.

          9.
Assignment and Subletting. Any public offering of the securities of Lessee shall
not constitute an assignment requiring consent.

          10.
Brokerage Fees. Lessor shall be responsible for all fees due to CRESA Partners and
Cornish & Carey in connection with the transactions relating to this Amendment pursuant to Lessor’s
written agreements with such brokers. Each party shall indemnify, defend and hold the other party
harmless from any claims that may be asserted against the other party by any broker, finder or
other person with whom such party has dealt.

          11.
Miscellaneous. Except as amended herein, the Lease shall remain in full force and
effect. This Amendment constitutes the entire agreement between the parties with respect to the
subject matter hereof.

          IN WITNESS WHEREOF, the parties have executed this Second Amendment to Lease as of the
11th day of February, 2005.

	 	 	 	 	 
	 	LESSOR:

CALIFORNIA PACIFIC COMMERCIAL CORPORATION,

 	 
	 	By:  	/s/
Dan McGanney III
 	 
	 	 	Its: President 	 
	 	 	 	 
	 

	 	 	 	 	 
	 	LESSEE:

ALEXZA MOLECULAR DELIVERY CORPORATION

 	 
	 	By:  	/s/ August J. Moretti	 
	 	 	Its: CFOexv10w13

 

	 	 	 	 	 

Exhibit 10.13

Development Agreement

     THIS DEVELOPMENT AGREEMENT dated as Oct 3, 2005, (the “Effective Date”) by and
between Alexza Pharmaceuticals, Inc., of 1020 East Meadow Circle, Palo Alto, CA 94303 (“Alexza”),
and Autoliv ASP, Inc. of 3350 Airport Road, Ogden, UT 84405 (“Autoliv”).

Recitals

     A. Alexza is in the business of development, manufacture and commercialization of a
proprietary thermal delivery technology to deliver drugs locally and systemically through the
lung; and

     B. Autoliv is in the business of development and commercialization of, among other things,
incendiary initiators; and

     C. Alexza desires to have Autoliv develop and supply to Alexza a Heat Packages that can be
incorporated in Alexza’s proprietary drug delivery device for sale by Alexza worldwide.

     IN CONSIDERATION of the respective covenants, representations, warranties and agreements set
forth herein, and intending to be legally bound hereby, the parties hereby agree as follows:

ARTICLE 1

Definitions

In this Agreement the following words will have the following meanings:

     1.1 “Affiliate” means with respect to an entity, a person, corporation or other entity that,
directly or indirectly, through one or more intermediaries, controls, is controlled by or is under
common control with that entity.

     1.2 “Agreement” means this Development Agreement and all of the terms and conditions herein.

     1.3 “Alexza Know-How” means all information and data (including but not limited to results),
technical information, trade secrets, specifications, instructions, processes, formulae, expertise
and information (i) owned by or licensed (with right to grant sublicenses) to Alexza; and (ii)
necessary or useful to the manufacture, use or sale of the Product or Heat Packages, including,
without limitation, biological, chemical, biochemical, physical and analytical, safety, quality
control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise
and information, which may be useful in studying, testing, the development, production, formulation
or use of the Product or Heat Packages.

     1.4 “Alexza Patents” means all patents and patent applications owned by or licensed (with the
right to grant sublicenses) to Alexza which have issued as of the Effective Date or which issue
from applications pending as of the Effective Date or which cover any New Discoveries, and which
(i) claim inventions necessary or useful to the manufacture, use or sale of

1.

 

the Product or Heat Packages, and (ii) have not expired or been held invalid or unenforceable by
a court of competent jurisdiction in a final, unappealable decision, including without limitation
all substitutions, re-examinations, reissues, extensions, registrations and supplementary or
complementary certificates.

     1.5 “Autoliv Know-How” means all information and data (including but not limited to results),
technical information, trade secrets, specifications, instructions, processes, formulae, expertise
and information: (i) owned by or licensed (with right to grant sublicenses) to Autoliv; and (ii)
necessary or useful to the manufacture, use or sale of the Heat Packages, including, without
limitation, biological, chemical, biochemical, physical and analytical, safety, quality control,
manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and
information, which may be useful in studying, testing, the development, production, formulation or
use of the Heat Packages.

     1.6 “Autoliv Patents” means all patents and patent applications owned by or licensed (with
the right to grant sublicenses) to Autoliv which have issued as of the Effective Date or which
issue from applications pending as of the Effective Date or which cover any New Discoveries, and
which (i) claim inventions necessary or useful to the manufacture, use or sale of the Heat
Packages, and (ii) have not expired or been held invalid or unenforceable by a court of competent
jurisdiction in a final, unappealable decision, including without limitation all substitutions,
re-examinations, reissues, extensions, registrations and supplementary or complementary
certificates.

     1.7 “Background Technology” shall have the meaning set forth in Article 6.1.

     1.8 “Confidential Information” means, subject to the limitations set forth in Article 8.2
hereof, all information disclosed by a party hereto to the other party pursuant to this Agreement,
the Consultant Services Agreement or pursuant to the Mutual Confidential Disclosure Agreement
between the parties dated as of November 3, 2004. In particular, Confidential Information shall be
deemed to include, but is not limited to, information relating to research and development programs
and results, prototypes and products, clinical and preclinical data, trade secrets, business
strategy, patent applications, licenses, suppliers’ and manufacturers’ identities, product and
marketing strategy, customers, market data, personnel and consultants.

     1.9 “Consultant Services Agreement” means the Consultant Services Agreement between the
parties dates as of December 17, 2004.

     1.10 “Development Plan” means the plan for the development of the Heat Packages, including
procedures, cost estimates and budget, time schedule and other information delivered and agreed to
following the Effective Date by the parties as more fully set forth in Article 2 below.

     1.11 “Development Plan Budget” means the budget set forth in the Development Plan.

     1.12 “Development Program” means the program for developing and optimizing the Heat Packages
for incorporation into the Product pursuant to the Development Plan.

2.

 

     1.13 “FDA” means the United States Food and Drug Administration, or its functional equivalent
in jurisdictions outside the United States.

     1.14 “Heat Package” means a heating substrate for the vaporization of a drug, consisting of a
chemical heat source sealed within an inert, stainless steel substrate.

     1.15 “Healthcare Field” means the areas of prevention, treatment, management, monitoring or
diagnosis of illness or disease.

     1.16 “Initiator Technology” means a method of initiating a chemical reaction, consisting of a
chemical reactant mixture deposited on a metal wire that is connected to an electric current
source.

     1.17 “Intellectual Property Rights” means all present and future worldwide trade secrets,
patent, patent applications, copyright, mask work or other proprietary or property right.

     1.18 “New Discoveries” means inventions, developments, improvements, enhancements or
modifications, whether or not patentable, that are conceived or developed or reduced to practice
by Alexza or Autoliv arising out of or in connection with Alexza or Autoliv’s performance under
this Agreement.

     1.19 “Product” means a system which includes pulsatile delivery technology and a drug or
drugs for Pulmonary Drug Delivery incorporating Alexza’s proprietary technology and Confidential
Information and the Heat Packages, and including anything used in or with the system for Pulmonary
Drug Delivery, or sold with or for use in or with the system for Pulmonary Drug Delivery.

     1.20 “Program Coordinator” shall have the meaning set forth in Article 2.2 (b)

     1.21 “Pulmonary Drug Delivery” shall mean delivery of drugs to the lungs.

     1.22 “Regulatory Approval” means any approval, licenses, registrations, or authorizations of
any federal, state or local regulatory agency, department, bureau or other government entity,
required for the manufacture, use, storage, import, transport or sale of Products in any country of
the Territory, including but not limited to investigational new drug applications (“IND”),
Investigational Device Exemptions (“IDE”), Pre-Market Notifications (“510(k)”) and/or Pre-Market
Approvals (“PMA”), European Commission (EC) Annex II CE Mark certifications, Doctor and Dentist
Exemption Certificates (“DDX”), Clinical Trials in Marketed Products (“CTMP”), Drug Master Files
(“DMF”), Biologic License Applications (“BLA”), New Drug Applications (“NDA”), Amended NDAs
(“ANDA”), national filings, Manufacturing Authorization Applications (“MAA”), MAA dossiers, MAA
renewals, MAA variations and Clinical Trials Exemptions (“CTX”).

     1.23 “Specifications” means the minimum specification for the manufacture and performance of
the Heat Packages, which shall be established by Alexza and agreed upon by the parties and
documented in the Development Plan.

     1.24 “Territory” means the world.

3.

 

     1.25
“Validation Heat Packages” means the production series of the Heat Packages appropriate
for design validation (type-testing) and human clinical trials, manufactured in conformance with
the Specifications by Autoliv and delivered to Alexza under this Agreement.

ARTICLE 2

Development Program

     2.1 Purpose and Scope. The parties wish to collaborate in the development of the Heat
Packages, to be incorporated in the Product for commercialization by Alexza worldwide. To that
end, the parties will embark on a Development Program with each party bearing specified
responsibilities, all as further described herein.

     2.2 Development Program.

          (a) Scope. Immediately after the execution hereof, the parties will commence the Development
Program, which shall encompass all activities necessary to develop the Heat Packages and
incorporate it into the Product for further clinical trials and commercial distribution.

          (b) Coordination of Development Program. To facilitate and coordinate the relationship of
Alexza and Autoliv with regard to the development of the Heat Packages, each party shall appoint
one (1) representative (“Program Coordinator”) who together shall jointly determine the mechanisms
required for the exchange of information (including Background Technology and Confidential
Information) with respect to all aspects of the Development Program.

          (c) Specifications.

               (i) The parties, through the Program Coordinators, shall develop mutually agreeable
Specifications for the Heat Packages based on the parameters set forth in the Development Plan
and the results of activities undertaken in the Development Program. If the parties are unable to
agree upon the Specifications, Alexza shall have the right to terminate the Agreement pursuant to
Article 5.3 or both parties may agree to terminate the Agreement pursuant to Article 5.2(b).

               (ii) Alexza shall have the right to propose modifications of the Specifications from time to
time. If Alexza recommends any modifications to the Specifications, Autoliv shall promptly notify
Alexza in writing of any additional costs and expenses associated with such modifications (the
“Additional Costs and Expenses”), including a reasonably detailed explanation of the reasons for
such additional costs and expenses, and any necessary revisions to the time schedule set forth in
the Development Plan. Alexza shall have four (4) weeks to notify Autoliv in writing either that:
(i) Alexza accepts such Additional Costs and Expenses and Autoliv is to proceed with such
modified Specifications, or (ii) withdraw such modified Specifications. If Alexza does not notify
Autoliv of its decision within the four (4) week period specified above, the modifications shall
be deemed withdrawn, and Autoliv shall proceed with the Development Program and the
Specifications as then in effect. If Alexza accepts such Additional Costs and Expenses, Autoliv
shall incorporate such modifications into the

4.

 

Specifications and proceed with the Development Program, subject to any modified time schedule
described above. Alexza shall bear the Additional Costs and Expenses. If the modifications to the
Specifications are necessitated by requirements of FDA or other regulatory authority, the parties
shall amend the Development Plan to reflect such modifications, and Alexza will bear the
Additional Costs and Expenses. If the parties are unable to agree upon any modifications to the
Specifications, Alexza shall have the right to terminate the Agreement pursuant to Article 5.3 or
both parties may agree to terminate the Agreement pursuant to Article 5.2(b).

          (d) Development Plan. The parties hereby agree to conduct and cooperate in the development
and optimization of the Heat Packages for incorporation in the Product, in accordance with the
Development Plan, and any and all amendments, revisions or elaboration to such plan to which the
parties agree in writing. Prior to each phase of the Development Plan, a proposed plan of
activities to be conducted during such phase shall be submitted to the Program Coordinators for
review and approval.

          (e) Conduct of Development Program.

               (i) Autoliv’s
Obligations. Autoliv shall use its good faith business and scientific judgment
as applied to commercial development projects, to allocate sufficient time, effort, equipment and
facilities to carry out the Development Plan in accordance with the timelines set forth therein.
Autoliv shall work diligently, consistent with accepted business practices and legal requirements,
to develop the Heat Packages and cooperate with Alexza’s efforts to incorporate it into the
Product, devoting the same degree of attention and diligence to such development efforts that it
devotes to development activities for its own products, but in no event less than reasonable
attention and diligence. Autoliv shall conduct its efforts hereunder in strict accordance with all
applicable laws, regulations and guidelines, including without limitation, the requirements for
Regulatory Approval.

               (ii) Alexza’s Obligations. Alexza shall use its good faith business and scientific judgment
as applied to commercial development projects, to allocate sufficient time, effort, equipment and
facilities to carry out its obligations under the Development Plan, and to promptly evaluate each
iteration of the Heat Packages prototype to enable Autoliv to meet its performance deadlines.
Alexza shall conduct its efforts hereunder in strict accordance with all applicable laws,
regulations and guidelines, including without limitation, the requirements for Regulatory
Approval.

               (iii) Quality Agreement. The parties shall negotiate in good faith a Quality Agreement to be
entered into not later than August 1, 2006 covering the Heat Packages to be manufactured pursuant
to the Development Plan.

          (f) Site
Visits. Autoliv shall allow Alexza, during Autoliv’s normal business hours, to
visit its place of business where the Heat Packages development work is being performed (the
“Development Work Site”) to inspect the status of such work. Alexza’s representative shall be
subject to Autoliv’s customary restrictions with respect to non-employee visitors to Autoliv’s
place of business and the Development Work Site.

5.

 

          (g) cGMP and QSR Compliance Audits. In addition to the site visits described above, Alexza
shall have the right to have its representatives visit the Development Work Site to review
Autoliv’s operations and assess its compliance with cGMP, ISO, QSR, and other applicable
regulatory requirements and quality assurance standards, and to discuss any related issues with
Autoliv’s development, manufacturing and management personnel. Autoliv shall supply to Alexza any
relevant documents necessary to permit Alexza to complete such review and assessment.

          (h) Regulatory Inspections. Autoliv shall cooperate with any inspection of its facilities by
a regulatory agency or authority in the Territory, including but not limited to any inspection by
such regulatory agency or authority prior to the granting of Regulatory Approval to market the
Products in the Territory (by mutual recognition of another jurisdiction’s Regulatory Approval or
otherwise). Autoliv shall notify Alexza as soon as possible of any notification received by
Autoliv from any regulatory authority in the Territory to conduct an inspection of its
manufacturing or other facilities used in the manufacturing, packaging, storage or handling of
Products, or relating to any claim of non-compliance with regulatory requirements. Copies of all
correspondence and notices relevant to the Heat Packages to and from the regulatory authority in
the Territory will be provided by Autoliv to Alexza.

          (i) Records. Autoliv will maintain for a period of ten (10) years all records generated in
the course of its performance under this Agreement and necessary to evidence compliance with (i)
such laws and regulations as are applicable to the design and manufacture of medical devices and
(ii) Heat Packages Specifications.

          (j) Deliverables.

               (i) Prototypes. The parties agree and understand that the development of the Heat Packages
is expected to be an iterative process, with prototypes created by Autoliv pursuant to the
then-effective Specifications, and that Alexza shall evaluate and test all prototypes in an
effort to further refine and define the final Specifications for the Validation Heat Packages.
Accordingly, Autoliv shall deliver all prototypes of the Heat Packages to Alexza in the
quantities and in accordance with the schedule and Specifications set forth in the Development
Plan.

               (ii) Disclosure and Reports. Autoliv shall fully and promptly disclose to Alexza, in writing
and on an on-going basis, all results, including but not limited to any New Discoveries, made in
the course of the Development Program. Autoliv shall provide to Alexza on a monthly basis during
the term of this Agreement a report setting forth, in such reasonable detail as Alexza may
request, (i) the work performed by Autoliv during such month, (ii) the status of the work to be
performed under the Development Plan as of the end of the month, (iii) a description of any
problems, if any, in completing the remaining work to be done in accordance with the schedule set
forth in the Development Plan and the proposed resolution of such problems, (iv) any other
information reasonably deemed relevant by Autoliv and (v) any other information related to the
Development Work reasonably requested by Alexza. Upon request of Alexza, Autoliv will make its
Program Coordinator available to discuss with Alexza’s Program Coordinator the status of the work
to be performed under the Development Plan and the work remaining to be done thereunder or such
other issues as arise with respect to the

6.

 

Development Program.

     2.3 Acceptance and Rejection of Prototypes.

          (a) Inspection. Alexza shall inspect all Heat Packages prototypes and other items delivered
pursuant to the Development Plan promptly upon receipt. Alexza may reject any Heat Packages
prototypes that do not conform to the Specifications at the time of delivery by Autoliv. Any such
rejection shall be made in writing and shall indicate the reasons for such rejection and, where
appropriate, shall be accompanied by test results or other documentation or data supporting
Alexza’s reason for rejection. Any rejection delivered within the time period specified in the
Development Plan for review of Heat Packages prototypes and other deliverables shall be deemed
timely. If Alexza does not deliver the notice of rejection within the time permitted under the
Development Plan, Alexza shall be deemed to have accepted that Heat Packages prototype. Acceptance
of an iteration of the Heat Packages prototype or other deliverable shall not prejudice Alexza’s
right to determine that a subsequent Heat Packages prototype or deliverable is not reasonably
acceptable.

          (b) Remediation of Rejection. After notice of rejection is received by Autoliv, the parties
shall discuss in good faith the reasons for such rejection, and Autoliv shall use reasonable and
timely efforts to promptly correct the deficiencies. The parties shall discuss in good faith any
adjustments to the schedule contained in the Development Plan necessitated by such correction
work, and Autoliv shall use reasonable efforts to assign such additional personnel to the
Development Program to minimize such delays. If Alexza determines that the Heat Packages prototype
does not meet the Specifications, or other deliverables do not meet the applicable requirements,
Alexza may elect, in its sole discretion, to (i) have Autoliv rework such Heat Packages prototype
or other deliverable, or (ii) terminate the Agreement pursuant to Article 5.3 or both parties may
agree to terminate the Agreement pursuant to Article 5.2(b).

          (c) Validation Heat Packages. In accordance with the time schedule set forth in the
Development Plan, Autoliv will deliver to Alexza the number of Validation Heat Packages set forth
in the Development Plan in accordance with the final Specifications. Promptly upon receipt of the
Validation Heat Packages, Alexza will inspect and test such Validation Heat Packages for
compliance with the Specifications. If the Validation Heat Packages do not comply with the
Specifications, Alexza may elect, in its sole discretion, to (i) have Autoliv rework such
Validation Heat Packages, or (ii) terminate the Agreement pursuant to Article 5.3 or both parties
may agree to terminate the Agreement pursuant to Article 5.2(b). Autoliv shall use diligent
efforts to make up any time lost due to replacement of Validation Heat Packages pursuant to this
Article. If the Validation Heat Packages comply with the Specifications and, as determined at
Alexza’s sole discretion, can be effectively used for their intended use, then Alexza will
determine within six (6) weeks after receipt of such Validation Heat Packages whether: (i) to
accept such Validation Heat Packages; or (ii) recommend modifications thereto, and will notify
Autoliv of its decision in writing. If Alexza does not so notify Autoliv within the time provided,
Alexza will be deemed to have accepted such Validation Heat Packages.

     2.4 Regulatory Filings.

7.

 

          (a) Clinical Trials. Alexza shall be responsible for conducting such clinical trials of the
Product as are necessary to obtain Regulatory Approval in the Territory.

          (b) Regulatory Filings. Alexza shall be responsible for obtaining all required Regulatory
Approval, in its own name. Autoliv shall provide regulatory and technical information pertaining
to the development and manufacture of the Heat Packages and cooperate with Alexza and the
responsible regulatory bodies to assist Alexza in obtaining the required Regulatory Approval.

     2.5 Development Costs. Alexza and Autoliv shall fund the development of the Heat Packages
under this Article 2 in accordance with the Development Plan Budget attached to the Development
Plan. The overall costs of completing the Development Program will be shared equally by Alexza
and Autoliv.

ARTICLE 3

Exclusivity

     3.1 Exclusivity. Autoliv shall work exclusively with Alexza on the development and
commercialization of a device or component to be used as part of a system for Pulmonary Drug
Delivery. Following expiration or termination of this Agreement, for a period of twenty-four (24)
months, Autoliv agrees that it shall not, by itself or with any third party, develop or
commercialize any device or component to be used as a part of a system for Pulmonary Drug Delivery,
except in conjunction with Alexza

     3.2 Covenants of Non-Use. Subject to Section 6.3, Autoliv hereby covenants that it shall not
(i) use, at any time, Alexza Know-How, Alexza Patents, New Discoveries or Alexza Confidential
Information for any purposes other than the development and manufacture of a Heat Packages for
incorporation into the Product, and (ii) use, during the term of this Agreement, the New
Discoveries in the Healthcare Field for any purposes other than the development and manufacture of
Heat Packages for Alexza.

ARTICLE 4

Supply Agreement

     4.1 Supply Agreement. Subject to the terms of this Agreement and the Development Plan, if
Alexza accepts the Validation Heat Packages as set forth above in Article 2.3(c) not later than
July 1, 2007, the parties shall negotiate in good faith for a period of up to sixty (60) days a
definitive Supply Agreement for the manufacture and delivery to Alexza of clinical trial and
commercial quantities of Heat Packages (“Initial Supply Agreement”). Certain initial terms of the
Initial Supply Agreement are set forth in the Initial Supply Agreement Terms separately agreed to
by the parties on the date hereof. If the parties are unable to negotiate and execute the Initial
Supply Agreement within such sixty (60) day period, then Alexza may terminate this Agreement as
set forth below in Article 5.3 or both parties may agree to terminate the Agreement pursuant to
Article 5.2(b).

ARTICLE 5

8.

 

Term and Termination

     5.1 Term. The term of this Agreement shall commence upon the Effective Date and, unless
sooner terminated as provided in this Article 5, expire on December 31, 2007.

     5.2 Termination By Either Party.

          (a) Breach. Each party shall have the right to terminate this Agreement and its obligations
hereunder in the event of a material breach by the other party, which breach remains uncured for
thirty (30) days after written notice is provided to the breaching party.

          (b) Termination by Mutual Consent. This Agreement may be terminated by the mutual consent of
Alexza and Autoliv.

     5.3 Termination by Alexza. Alexza shall have the right to terminate this Agreement (i) during
the period prior to the acceptance of the Validation Heat Packages described in Article 2.3(c),
upon sixty (60) days written notice to Autoliv for any reason, and (ii) and at the end of the
sixty (60) day period referenced in Article 4.1 if the parties have not entered into a Supply
Agreement.

     5.4 Effect of Termination by Alexza. If Alexza terminates this Agreement under Article 5.3,

          (a) Work in Progress. Autoliv shall deliver to Alexza in an expeditious manner all work in
progress developed hereunder or pursuant to the Development Plan, including all technical
documentation related to such work;

          (b) Payments. Alexza will pay Autoliv according to the Development Plan Budget for the period
up through the termination and Alexza will repay Autoliv $277,777.78 for each calendar quarter, or
portion thereof on a pro rated basis, since the Effective Date;

          (c) License. Effective upon such termination or the expiration of this Agreement, Autoliv
shall and hereby does grant to Alexza an exclusive, worldwide license (with the right to
sublicense through multiple tiers) under the AutoLiv Know-How and Autoliv Patents to develop,
make, have made, use, sell, offer to sell and import the Heat Packages as incorporated in
Products;

          (d) Technology Transfer. Autoliv shall disclose and transfer to Alexza, including, without
limitation, through visitations and observation of the pilot line facility, all data, know-how,
technology and other information reasonably necessary for Alexza to understand and duplicate the
processes employed by Autoliv in the manufacture of the Heat Packages in accordance with the
Specifications, and provide Alexza with access to Autoliv personnel as reasonably required by
Alexza to transition to Alexza all development and

9.

 

manufacturing activity for the Heat Packages; and

          (e) Royalty. Alexza will pay to Autoliv a royalty of $.04 per Product for each Product sold
by Alexza, its affiliates and sublicensees that incorporates Autoliv’s Background Technology (the
“Termination Royalty”). The Termination Royalty shall cease on the later of (i) the expiration of
any Autoliv Patents included in Autoliv’s Background Technology, and (ii) ten (10) years after the
Effective Date, if the Autoliv Background Technology includes only Autoliv Know-How and is not
covered by any claim of any Autoliv Patent. These determinations shall be made on a country by
country basis. The Termination Royalty shall be paid quarterly. Autoliv shall have the right to
audit at its expense Alexza’s records relating to the sales of Product by Alexza to ascertain
proper accounting for prompt payment of the Termination Royalty, upon reasonable advance notice to
Alexza and in a manner that does not interfere with Alexza’s business.

     5.5 Effect of Termination by Autoliv. In the event that Autoliv terminates this Agreement
under Article 5.2(a) or both parties agree to terminate the Agreement pursuant to Section 5.2(b),
then Alexza shall promptly pay to Autoliv any outstanding amounts due hereunder or under the
Development Plan Budget. Autoliv shall then deliver to Alexza in an expeditious manner all work in
progress developed hereunder or pursuant to the Development Plan, including all technical
documentation related to such work.

     5.6 Accrued Obligations. Notwithstanding any termination under this Article 5, any obligation
to pay payments which had accrued or become payable as of the date of termination shall survive
termination of this Agreement.

     5.7 Survival. Except as otherwise set forth in this Agreement, the following provisions shall
survive termination or expiration of this Agreement: Articles 5.4, 5.5, 5.6, 5.7, and Articles 6,
7, 8, 9 and 10.

ARTICLE 6

Intellectual Property

     6.1 Background Technology. Each party shall retain ownership and control of their respective
inventions, know-how, information, data and related Intellectual Property Rights existing as of the
Effective Date or generated outside the Development Program (collectively, a party’s “Background
Technology”). Except as otherwise set forth in this Agreement, nothing herein shall grant or imply
any license or right of use to any Background Technology of either party to the other party, except
as necessary for the performance of this Agreement.

     6.2 Inventorship. Inventorship of New Discoveries shall be determined in accordance with the
patent laws of the United States of America.

     6.3 Autoliv Inventions. Autoliv shall solely own all New Discoveries having sole utility in or
application to the use, application or method of manufacture of the Initiator Technology (the
“Transportation Initiator-Related Inventions”), whether made, conceived, reduced to practice or
generated by either party alone or both parties jointly, and Autoliv shall

10.

 

solely own all
Intellectual Property Rights covering Transportation Initiator-Related Inventions (the “Autoliv
Program IP”); provided, however, that Autoliv shall have no right to use, exploit, sublicense or
otherwise transfer any rights to such New Discoveries or such Intellectual Property Rights for any
use or potential use in the Healthcare Field. Alexza hereby assigns and transfers to Autoliv all
right, title and interest in and to all Autoliv Patents and Autoliv Know-How and Autoliv shall
have the right to obtain and hold in its own name all registrations or any such other similar
protection for any of such Autoliv Patents or Autoliv Know-How.

     6.4 Alexza Inventions. Alexza shall solely own all New Discoveries, whether made, conceived,
reduced to practice or generated by either party alone or both parties jointly, that are neither
improvements or modifications to Autoliv Background Technology or Transportation Initiator-Related
Inventions, and all Intellectual Property Rights covering such New Discoveries, or the Product
(exclusive of the Heat Packages) (collectively, “Alexza IP”). Such Alexza IP includes all Alexza inventions
conceived in connection with Autoliv’s work under this Agreement or the Consultant Services
Agreement, whether or not the inventions are actually reduced to practice or utilized in the
Product or Heat Packages. Autoliv shall have no ownership or license rights in the Alexza IP
unless Alexza grants such rights in connection with the Supply Agreement. Autoliv hereby assigns
and transfers to Alexza all right, title and interest in and to all Alexza IP, and Alexza shall
have the right to obtain and hold in its own name all registrations or any such other similar
protection for any of such Alexza IP.

     6.5 Exploitation. Alexza shall have the sole right to use the Alexza IP. Notwithstanding the
foregoing, Alexza hereby grants Autoliv a non-exclusive license to use the Alexza IP to the extent
necessary to conduct the Development Program during the term of this Agreement.

     6.6 License to Alexza of Autoliv Technology. Autoliv grants to Alexza an unrestricted,
nonexclusive, perpetual, fully paid-up, royalty-free (except as provided in Article 5.4(e))
worldwide license under the Autoliv Know-How and Autoliv Patents to use Autoliv’s Background
Technology and the Autoliv Program IP to develop, make, use, sell, offer for sale and import the
Product and all updates and revisions and improved versions thereto. Alexza shall have the right to
sublicense the license granted herein: (a) to subsidiaries and Affiliates of Alexza; (b) as part of
(and for use solely in conjunction with technology covered under) a bona fide license by Alexza to
a third party of any significant part of Alexza Inventions or Intellectual Property Rights owned by
Alexza hereunder; and to any successor to Alexza or acquiring entity of Alexza.

     6.7 Assistance. Each party shall, and hereby does, assign to the other party all or part of
the right, title and interest of such party in and to New Discoveries and related Intellectual
Property Rights, solely to the extent necessary to achieve the allocation of ownership of New
Discoveries and associated Intellectual Property Rights provided in this Articles 6. Each party
agrees to provide reasonable assistance to the other party, at the other party’s expense, in
obtaining and from time to time enforcing and defending the other party’s rights as set forth in
this Articles 6 to New Discoveries, including without limitation and as applicable, the
assignment to the other party of all or part of the right, title and interest of its employees or
independent contractors in and to such New Discoveries and associated Intellectual Property
Rights to achieve the allocation of ownership provided in this Articles 6.

11.

 

     6.8 Patent Applications. Each party shall have the right, but not the obligation, to file,
prosecute, maintain, enforce and defend any patents which claim New Discoveries which such party
owns pursuant to this Article 6.

ARTICLE 7

Indemnification

     7.1 Indemnification by Alexza. Alexza hereby agrees to indemnify, hold harmless and defend
Autoliv against any and all expenses, costs of defense (including without limitation attorneys’
fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts
Autoliv becomes legally obligated to pay because of any third party claim or claims against it to
the extent that such claim or claims (i) arise out of the breach or alleged breach of any
representation or warranty by Alexza hereunder, or (ii) arise from a third party claim of injury or
death or damage to property resulting from such third party’s use of the Product and not caused by
Autoliv’s negligence or misconduct in the performance of its obligations under this Agreement, or
(iii) are due to the negligence or misconduct of Alexza in the promotion, marketing or sale of the
Product; provided that such indemnification obligation shall not apply to the extent such claims
are covered by Autoliv’s indemnity set forth in Article 7.2 below.

     7.2 Indemnification by Autoliv. Autoliv hereby agrees to indemnify, hold harmless and defend
Alexza against any and all expenses, costs of defense (including without limitation attorneys’
fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts
Alexza becomes legally obligated to pay because of any claim or claims against it to the extent
that such claim or claims (i) result from Autoliv’s activities under this Agreement, (ii) arise out
of the breach or alleged breach of any representation or warranty by Autoliv hereunder, (iii) are
due to the negligence or misconduct of Autoliv, or (iv) arise from a third party claim of injury or
death or damage to property resulting from such third party’s use of the Product to the extent
caused by Autoliv’s negligence or misconduct in the performance of its obligations under this
Agreement; provided that, such indemnification shall not apply to the extent such claims are
covered by Alexza’s indemnity set forth in Article 7.1 above.

     7.3 Procedure. Each Party’s agreement to indemnify, defend and hold the other harmless under
Articles 7.1 and 7.2 is conditioned on the indemnified party (a) providing written notice to the
indemnifying party of any claim arising out of the indemnified activities within thirty (30) days
after the indemnified party has knowledge of such claim; (b) permitting the indemnifying party to
assume full responsibility to investigate, prepare for and defend against any such claim; (c)
assisting the indemnifying party, at the indemnifying party’s reasonable expense, in the
investigation of, preparation for and defense of any claim; and (d) not compromising or settling
such claim with the indemnifying party’s written consent. In the event that the parties cannot
agree as to the application of Articles 7.1 and 7.2 above to any particular loss or claim, the
parties may conduct separate defenses of such claim. Each party further reserves the right to claim
indemnity from the other in accordance with Articles 7.1 and 7.2 above upon resolution of the
underlying claim, notwithstanding subsection (b) above.

     7.4 Insurance Coverage. Each party represents and warrants that it is covered and will
continue to be covered by a comprehensive insurance program which covers all of each

12.

 

Party’s activities and obligations hereunder. Each party shall provide the other party with
written notice at least fifteen (15) days prior to any cancellation or material change in such
insurance program that reduces coverage thereunder. Each party shall maintain such insurance
program, or other program with comparable coverage, beyond the expiration or termination of this
Agreement during (i) the period that any Heat Pack produced pursuant to this agreement is intended
to be used in a Product for clinical trials and (ii) a commercially reasonable period thereafter.

ARTICLE 8

Confidentiality

     8.1
Confidential Information; The parties’ rights and obligations with respect to Confidential
Information disclosed under this Agreement shall be governed by the Mutual Confidential Disclosure
Agreement between the parties dated as of November 3, 2004, except as set forth below.

     8.2
Authorized Disclosure. The parties agree that the terms of the Agreement, the Initial
Supply Agreement Terms and the Development Plan will be considered Confidential Information of both
parties. Notwithstanding the foregoing, either party may make disclosures required by law or
regulation, provided prior notice is given to the other party whenever possible, and may disclose
the terms of the Agreement, the Initial Supply Agreement Terms and the Development Plan to bona
fide potential corporate partners, and to financial underwriters, prospective investors, acquirers
and merger partners, and other parties with a need to know such information. Any such disclosures,
and any disclosure of the development and marketing of Products or other developments under this
Agreement, including but not limited to press releases, will be reviewed and consented to by each
party prior to such disclosure. Such consent shall not be untimely or unreasonably withheld by
either party. All such disclosures shall be made only to parties under an obligation of
confidentiality.

Notwithstanding any other provision of this Agreement, each party may disclose Confidential
Information if such disclosure:

          (a) is in response to a valid order of a court or other governmental body of the United States
or a foreign country, or any political subdivision thereof; provided, however, that the responding
party shall first have given notice to the other party hereto and shall have made a reasonable
effort to obtain a protective order requiring that the Confidential Information so disclosed be
used only for the purposes for which the order was issued;

          (b) is otherwise required by law or regulation, including SEC related documents; or

          (c) is otherwise necessary to file or prosecute patent applications, prosecute or defend
litigation or comply with applicable governmental regulations or otherwise establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is
necessary.

     8.3
Return of Confidential Information. Upon termination of this Agreement, each

13.

 

party shall use diligent efforts (including without limitation a diligent search of files and
computer storage devices) to return all Confidential Information received by it from the other
party, provided, however, that the receiving party may keep one copy of such Confidential
Information for legal archival purposes. Access to the copy so retained by the receiving party’s
legal department shall be restricted to counsel and such Confidential Information shall not be
used except in the resolution of any claims or disputes arising out of this Agreement.

     8.4 Publications. Except as required by law, neither party shall publish or present the
results of studies carried out with respect to Products without the opportunity for prior review
by the other party. Each party shall provide to the other the opportunity to review any proposed
abstracts, manuscripts or presentations which relate to Products at least thirty (30) days prior
to their intended submission for publication and such submitting party agrees, upon written
request from the other party, not to submit such abstract or manuscript for publication or to
make such presentation until the other party is given a reasonable period of time to seek patent
protection for any material in such publication or presentation that it believes is patentable.

ARTICLE 9

Representations and Warranties

     9.1 Mutual Representations and Warranties. Each party hereby represents and warrants:

          (a) Corporate Power. Such party is duly organized and validly existing under the laws of the
state or nation of its incorporation and has full corporate power and authority to enter into this
Agreement and to carry out the provisions hereof.

          (b) Due Authorization. Such party is duly authorized to execute and deliver this Agreement and
to perform its obligations hereunder.

          (c) Binding Agreement. This Agreement is a legal and valid obligation binding upon it and is
enforceable in accordance with its terms. The execution, delivery and performance of this
Agreement by such party does not conflict with any agreement, instrument or understanding, oral
or written, to which it is a party or by which it may be bound, nor violate any law or regulation
of any court, governmental body or administrative or other agency having authority over it.

     9.2 Alexza Representations and Warranties. Alexza warrants and represents that:

          (a) Alexza is the owner of the entire right, title and interest in and to the Alexza Patents
and the Alexza Know-How, and has not granted, nor during the term of the Agreement will grant, any
right to any third party relating to the Alexza Patents, the Alexza Know-How, or its interest in
the New Discoveries, which would conflict with the rights granted to Autoliv hereunder.

          (b) Alexza has received no notice or other communication from a third party

14.

 

that the practice of the Alexza Background Technology, Alexza Patents or the Alexza Know-How
infringes such third party’s intellectual property rights.

          (c) To the best of Alexza’s knowledge, no third party is infringing Alexza’s rights under the
Alexza Patents or the Alexza Know-How.

     9.3 Autoliv Representations and Warranties. Autoliv warrants and represents that:

          (a) Autoliv is the owner of the entire right, title and interest in and to the Autoliv
Patents and the Autoliv Know-How, and has not granted, nor during the term of the Agreement will
grant, any right to any third party relating to the Autoliv Patents, the Autoliv Know-How, or its
interest in the New Discoveries or Transportation Initiator-Related Inventions, which would
conflict with the rights granted to Alexza hereunder.

          (b) Autoliv has received no notice or other communication from a third party that the
practice of the Autoliv Background Technology, Autoliv Patents or the Autoliv Know-How infringes
such third party’s intellectual property rights.

          (c) To the best of Autoliv’s knowledge, no third party is infringing Autoliv’s rights under
the Autoliv Patents or the Autoliv Know-How.

     9.4 Product Warranty. Autoliv warrants to Alexza that the Heat Packages supplied to Alexza
under this Agreement shall (i) meet the Specifications; (ii) be manufactured, packaged, labeled
and stored in compliance with all applicable laws, rule and regulations applicable to such
products; and (iii) be free from defects in material and workmanship.

ARTICLE 10

Miscellaneous

     10.1 Agency. Neither party is, nor will be deemed to be, an employee, agent or legal
representative of the other party for any purpose. Neither party will be entitled to enter into any
contracts in the name of, or on behalf of the other party, nor will a party be entitled to pledge
the credit of the other party in any way or hold itself out as having authority to do so. This
Agreement is an arm’s-length agreement between the parties and shall not constitute or be construed
as a joint venture.

     10.2 Assignment. Except as otherwise provided herein, neither this Agreement nor any interest
hereunder will be assignable in part or in whole by any party without the prior written consent of
the other; provided, however, that either party may assign this Agreement to any of its Affiliates
or to any successor by merger or sale of all or substantially all of its business assets to which
this Agreement relates in a manner such that the assignor will remain liable and responsible for
the performance and observance of all its duties and obligations hereunder. This Agreement will be
binding upon the successors and permitted assigns of the parties and the name of a party herein
will be deemed to include the names of such party’s successors and permitted assigns to the extent
necessary to carry out the intent of this Agreement. Any assignment which is not in accordance with
this Article 10.2 will be void.

15.

 

     10.3 Employees. Autoliv and Alexza shall have a written agreement with each of its employees
and consultants requiring them to comply with obligations with respect to intellectual property
set forth in Article 6 and confidentiality set forth in Article 8. Alexza is permitted to solicit
the services of, or offer employment to, any person who is or was an employee of Autoliv.

     10.4 Amendment. No amendment or modification hereof shall be valid or binding upon the
parties unless made in writing and signed by both parties.

     10.5 Notices. Any notice or other communication required or permitted to be given to either
party hereto shall be in writing unless otherwise specified and shall be deemed to have been
properly given and to be effective on the date of delivery if delivered in person or by facsimile
or overnight courier, or three (3) days after mailing by registered or certified mail, postage
paid, to the other party at the following address:

               In the case of Alexza:

	 	 	 
	 

	 	Alexza Pharmaceuticals, Inc.
	 

	 	Attention: President and CEO and separate copy to CFO
	 

	 	1020 E. Meadow Circle
	 

	 	Palo Alto, CA 94303
	 

	 	Facsimile Number: (650) 687-3999
	 
	 	 
	 

	 	and
	 
	 	 
	 

	 	Cooley Godward LLP
	 

	 	Attention: Brent D. Fassett
	 

	 	380 Interlocken Crescent, Suite 900
	 

	 	Broomfield, CO 80021
	 

	 	Facsimile Number: (720) 566-4099

               In the case of Autoliv :

	 	 	 
	 

	 	Autoliv ASP, Inc.
	 

	 	Attention: President
	 

	 	3350 Airport Road
	 

	 	Ogden, Ut 84405
	 
	 	 
	 

	 	Telephone: (801) 629-9190
	 

	 	FAX: (801) 629-9189
	 

	 	Attention: Mike Ward
	 
	 	 
	 

	 	and

               Either party may change its address for communications by a notice to the other party in
accordance with this Article 12.4.

     10.6 Force Majeure. Any prevention, delay or interruption of performance by any

16.

 

party under this Agreement shall not be considered a breach of this Agreement if and to the extent
caused by occurrences beyond the reasonable control of the party affected, including but not
limited to acts of God, embargoes, strikes or other concerted acts of workers, fire, flood,
earthquake, explosion, riots, wars, civil disorder, rebellion or sabotage. The party suffering
such occurrence shall immediately notify the other party and any time for performance hereunder
shall be extended by the actual time of prevention, delay, or interruption caused by the
occurrence.

     10.7 Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon
the parties and their respective successors and permitted assigns.

     10.8 Export Control. This Agreement is made subject to any restrictions concerning the export
of products or technical information from the United States of America or other countries that may
be imposed upon or related to Alexza or Autoliv from time to time. Each party agrees that it will
comply with all applicable export laws and regulations in connection with its activities under
this Agreement.

     10.9 Severability. If any term, condition or provision of this Agreement is held to be
unenforceable for any reason, it shall, if possible, be interpreted, to achieve the intent of the
parties to this Agreement to the extent possible rather than voided. If not capable of such
interpretation, the parties shall in good faith seek to agree on an alternative provision
reflecting the intent of the parties which is enforceable. In any event, all other terms,
conditions and provision of this Agreement shall be deemed valid and enforceable to the full
extent.

     10.10 Governing Law and Construction. The validity, construction and performance of this
Agreement shall be governed by the substantive law the State of New York, and the United States of
America, excluding that body or law related to choice of law. Any action or proceeding brought by
Alexza to enforce the terms of this Agreement shall be brought in the County of Salt Lake, State of
Utah (if under State law) or the District Court of Utah (if under Federal Law). Any action or
proceeding brought by Autoliv to enforce the terms of this Agreement shall be brought in the County
of Santa Clara, State of California (if under State law) or the District Court for the Northern
District of California (if under Federal Law). The parties consent to personal jurisdiction before
such courts. If any provision of this Agreement is determined to be invalid or unenforceable, in
whole or in part, the remaining provisions shall remain in full force and effect.

     10.11 Cumulative Rights. The rights, powers and remedies hereunder shall be in addition to,
and not in limitation of, all rights, powers and remedies provided at law or in equity, or under
any other agreement between the parties. All of such rights, powers and remedies shall be
cumulative, and may be exercised successively or cumulatively.

     10.12 Waiver. No waiver by either party hereto on any breach or default of any of the
covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar
breach or default.

     10.13 Entire Agreement. This Agreement and the Mutual Non-Disclosure Agreement and all
Exhibits, Schedules and separately delivered documents referred to herein, embody the

17.

 

entire understanding of the parties with respect to the subject matter hereof and shall supersede
all previous communications, representations or understandings, either oral or written, between the
parties relating to the subject matter hereof. Effective upon the execution of this Agreement, the
Consultant Services Agreement is hereby terminated and has no further affect.

     10.14 Counterparts. This Agreement may be executed in one or more counterpart copies, each of
which shall be deemed an original and all of which taken together shall be deemed to constitute
one and the same instrument. This Agreement shall become binding when one or more counterparts
taken together shall have been executed and delivered by the parties.

18.

 

     10.15 Further Assurances. Each party shall execute such other instruments, give such further
assurances and perform such acts that are or may become necessary or appropriate to effectuate and
carry out the provisions of this Agreement.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their officers
thereunto duly authorized as of the date first set forth above.

	 	 	 	 	 	 	 
	Alexza Pharmaceuticals, Inc.

	 	 	 	Autoliv ASP, Inc.	 	 
	 
	 	 	 	 	 	 
	/s/
Thomas B. King

	 	 	 	/s/ Michael J. Ward	 	 
	 

	 	 	 	 	 	 
	Authorized Signatory

	 	 	 	Authorized Signatory
	 	 

19.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]